TapewireFind a company

person · Reporting owner

INGRAM ROBERT ALEXANDER

Disclosed activity across 9 companies

Tapewire entity
16884
SEC CIK
0001219890

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315DirectorFebruary 28, 2023March 02, 2023
Bausch Health Companies Inc.VRX · Entity 4363DirectorMarch 31, 2017April 04, 2017
G1 Therapeutics, Inc.GTHX · Entity 8741310% ownerMay 30, 2018June 01, 2018
LOWES COMPANIES INCLOW · Entity 2896DirectorMarch 31, 2011April 04, 2011
Novan, Inc.NOVN · Entity 111882DirectorJuly 28, 2020July 30, 2020
PhaseBio Pharmaceuticals IncPHAS · Entity 11330510% ownerOctober 22, 2018October 24, 2018
WOLFSPEED, INC.CREE · Entity 619DirectorOctober 17, 2018October 18, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOCRYST PHARMACEUTICALS INC

Report date February 28, 2023 · Filed March 02, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect100,198 Reported balance After 2023-02-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2023-02-28 · Grant · Acquired 2,259 · Balance 100,198

F1: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $20,000.

Bausch Health Companies Inc.

Report date March 31, 2017 · Filed April 04, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, no par valueSEC Table I · non-derivativeDirect92,046 Reported balance After 2017-03-31 transaction · row 1
1 source row

Row 1 · 2017-03-31 · Grant · Acquired 2,120 · Balance 92,046

F1: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnotes3,279,421 Reported balance After 2018-05-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes3,237,711 Reported balance After 2018-05-30 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

Filing footnotes · ownership attribution and instrument terms

F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.

F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.

F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.

LOWES COMPANIES INC

Report date March 31, 2011 · Filed April 04, 2011

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Phantom StockSEC Table II · derivative / convertible securityDirect32,429.879 Reported balance After 2011-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2011-03-31 · Grant · Acquired 709.421 · Balance 32,429.879

F1: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Novan, Inc.

Report date July 28, 2020 · Filed July 30, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2030-07-27Direct20,000 Reported balance After 2020-07-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-07-28 · Grant · Acquired 20,000 · Balance 20,000

F1: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in four equal quarterly installments, with the first installment vesting on October 28, 2020.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Hatteras Venture Partners I, LP52,690 Reported balance After 2018-10-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-10-22 · Conversion · Acquired 52,690 · Balance 52,690

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Common StockSEC Table I · non-derivativeIndirectBy Hatteras Venture Partners III, LP1,820,933 Last balance in matching sequence After 2018-10-22 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2018-10-22 · Conversion · Acquired 1,683,420 · Balance 1,683,420

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Row 3 · 2018-10-22 · Purchase · Acquired 137,513 · Balance 1,820,933

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Common StockSEC Table I · non-derivativeIndirectBy Hatteras Venture Affiliates III, LP163,099 Last balance in matching sequence After 2018-10-22 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 4 · 2018-10-22 · Conversion · Acquired 150,612 · Balance 150,612

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Row 5 · 2018-10-22 · Purchase · Acquired 12,487 · Balance 163,099

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Common StockSEC Table I · non-derivativeIndirectBy Catalysta Ventures, LLC4,846 Reported balance After 2018-10-22 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2018-10-22 · Conversion · Acquired 4,846 · Balance 4,846

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Common StockSEC Table I · non-derivativeIndirectBy Venture Capital Multiplier Fund416,481 Last balance in matching sequence After 2018-10-22 transaction · row 8 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 7 · 2018-10-22 · Conversion · Acquired 266,481 · Balance 266,481

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Row 8 · 2018-10-22 · Purchase · Acquired 150,000 · Balance 416,481

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12IndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2018-10-22 · Other · Disposed 19,061 · Balance 0

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP1,045,222 Reported balance After 2018-10-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2018-10-22 · Other · Acquired 19,061 · Balance 1,045,222

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP1,044,764 Reported balance After 2018-10-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2018-10-22 · Sale · Disposed 458 · Balance 1,044,764

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 30 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 30 · 2018-10-22 · Conversion · Disposed 1,044,764 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12IndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2018-10-22 · Other · Disposed 1,731 · Balance 0

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP94,916 Reported balance After 2018-10-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2018-10-22 · Other · Acquired 1,731 · Balance 94,916

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP94,874 Reported balance After 2018-10-22 transaction · row 14 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 14 · 2018-10-22 · Sale · Disposed 42 · Balance 94,874

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 31 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 31 · 2018-10-22 · Conversion · Disposed 94,874 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12IndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 15 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 15 · 2018-10-22 · Other · Disposed 47,458 · Balance 0

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP150,459 Reported balance After 2018-10-22 transaction · row 16 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 16 · 2018-10-22 · Other · Acquired 47,458 · Balance 150,459

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP149,320 Reported balance After 2018-10-22 transaction · row 17 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 17 · 2018-10-22 · Sale · Disposed 1,139 · Balance 149,320

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 32 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 32 · 2018-10-22 · Conversion · Disposed 149,320 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12IndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 18 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 18 · 2018-10-22 · Other · Disposed 4,309 · Balance 0

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP13,662 Reported balance After 2018-10-22 transaction · row 19 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 19 · 2018-10-22 · Other · Acquired 4,309 · Balance 13,662

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP13,558 Reported balance After 2018-10-22 transaction · row 20 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 20 · 2018-10-22 · Sale · Disposed 104 · Balance 13,558

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 33 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 33 · 2018-10-22 · Conversion · Disposed 13,558 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12IndirectBy Venture Capital Multiplier Fund0 Reported balance After 2018-10-22 transaction · row 21 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 21 · 2018-10-22 · Other · Disposed 41,414 · Balance 0

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Venture Capital Multiplier Fund41,414 Reported balance After 2018-10-22 transaction · row 22 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 22 · 2018-10-22 · Other · Acquired 41,414 · Balance 41,414

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Venture Capital Multiplier Fund40,420 Reported balance After 2018-10-22 transaction · row 23 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 23 · 2018-10-22 · Sale · Disposed 994 · Balance 40,420

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Venture Capital Multiplier Fund0 Reported balance After 2018-10-22 transaction · row 34 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 34 · 2018-10-22 · Conversion · Disposed 40,420 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series 1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners I, LP0 Reported balance After 2018-10-22 transaction · row 24 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 24 · 2018-10-22 · Conversion · Disposed 52,690 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series 1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 25 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 25 · 2018-10-22 · Conversion · Disposed 42,530 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series 1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 26 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 26 · 2018-10-22 · Conversion · Disposed 3,862 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series 1 Preferred StockSEC Table II · derivative / convertible securityIndirectBy Catalysta Ventures, LLC0 Reported balance After 2018-10-22 transaction · row 27 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 27 · 2018-10-22 · Conversion · Disposed 4,846 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series AA Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 28 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 28 · 2018-10-22 · Conversion · Disposed 174,699 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series AA Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 29 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 29 · 2018-10-22 · Conversion · Disposed 13,609 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Partners III, LP0 Reported balance After 2018-10-22 transaction · row 35 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 35 · 2018-10-22 · Conversion · Disposed 272,107 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectBy Hatteras Venture Affiliates III, LP0 Reported balance After 2018-10-22 transaction · row 36 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 36 · 2018-10-22 · Conversion · Disposed 24,709 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectBy Venture Capital Multiplier Fund0 Reported balance After 2018-10-22 transaction · row 37 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 37 · 2018-10-22 · Conversion · Disposed 226,061 · Balance 0

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.

F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.

F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

WOLFSPEED, INC.

Report date October 17, 2018 · Filed October 18, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
COMMON STOCKSEC Table I · non-derivativeDirect77,710 Reported balance After 2018-10-17 transaction · row 1
1 source row

Row 1 · 2018-10-17 · Grant · Acquired 760 · Balance 77,710

F1: Represents shares of Common Stock credited to the Reporting Person's 2018 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock credited to the Reporting Person's 2018 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Black Diamond Therapeutics, Inc.

Report date December 16, 2022 · Filed December 20, 2022

Section 16 reporting ended · disclosed 2022-12-20. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect42,854 Reported balance After 2022-12-16 transaction · row 1
1 source row

Row 1 · 2022-12-16 · Grant · Acquired 9,375 · Balance 42,854

F1: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

F2: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022.

Section 16 reporting ended · disclosed 2017-01-19. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote2,060,514 Last balance in matching sequence After 2017-01-19 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2017-01-17 · Sale · Disposed 9,806 · Balance 2,080,364

F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Row 2 · 2017-01-18 · Sale · Disposed 12,258 · Balance 2,068,106

F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Row 3 · 2017-01-19 · Sale · Disposed 7,592 · Balance 2,060,514

F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2017 Filed Sep 6, 2017 20:23 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 7,033 $0.00 $0.00
Disclosure

SEC source: 0000895419-17-000078 · wf-form4_150472937934989.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,974

F1 · kind: Award of restricted stock units vesting in full on September 1, 2018.

Read SEC document
August 29, 2017 Filed Aug 29, 2017 16:37 UTC Novan, Inc. NOVN · Entity 111882 PurchaseCommon Stock 8,465 $4.70 $39,785.50
Disclosure

SEC source: 0001209191-17-050599 · doc4.xml · nonDerivative · entry 2

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,777

F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.68 to $4.70, inclusive.

Read SEC document
August 25, 2017 Filed Aug 29, 2017 16:37 UTC Novan, Inc. NOVN · Entity 111882 PurchaseCommon Stock 3,535 $4.25 $15,023.75
Disclosure

SEC source: 0001209191-17-050599 · doc4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,312

F1 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.23 to $4.25, inclusive. The reporting person undertakes to provide to Novan, Inc., any security holder of Novan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

Read SEC document
August 23, 2017 Filed Aug 24, 2017 20:13 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 1,125 $22.21 $24,986.25
Disclosure

SEC source: 0000895419-17-000061 · wf-form4_150360560039455.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,941

F1 · kind: Represents shares of Common Stock credited to the Reporting Person's 2017 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Read SEC document
June 05, 2017 Filed Jun 7, 2017 17:56 UTC Novan, Inc. NOVN · Entity 111882 GrantStock Option (right to buy) · Derivative 34,014 $0.00 Strike: $4.64 $0.00
Disclosure

SEC source: 0001209191-17-038386 · doc4.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,014

Underlying: Common Stock · 34,014 shares

Expires 2027-06-04

F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on September 5, 2017.

Read SEC document
June 01, 2017 Filed Jun 2, 2017 20:04 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 1,941 $5.15 $9,996.15
Disclosure

SEC source: 0001127602-17-020306 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,764

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

Read SEC document
May 24, 2017 Filed May 25, 2017 15:48 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantAutomatic Stock Option Grant · Derivative 30,000 $0.00 Strike: $5.13 $0.00
Disclosure

SEC source: 0001127602-17-019333 · form4.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2027-05-24

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionSeries C Preferred Stock · Derivative 1,009,693 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 8

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 336,563 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F9 · ownership.nature: Includes shares of Series C Preferred Stock convertible into 294,493 shares of the Issuer's common stock held by HVP IV and shares of Series C Preferred Stock convertible into 42,070 shares of the Issuer's common stock held by L2 Ventures, LLC.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionSeries B Preferred Stock · Derivative 2,584,959 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 7

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 861,651 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F8 · ownership.nature: Includes shares of Series B Preferred Stock convertible into 804,208 shares of the Issuer's common stock held by HVP IV and shares of Series B Preferred Stock convertible into 57,443 shares of the Issuer's common stock held by L2 Ventures, LLC.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionSeries A Preferred Stock · Derivative 6,568,527 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 6

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,189,508 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F7 · ownership.nature: Includes shares of Series A Preferred Stock convertible into 1,990,276 shares of the Issuer's common stock held by HVP IV and shares of Series A Preferred Stock convertible into 199,232 shares of the Issuer's common stock held by Hatteras NC.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionSeries 1 Preferred Stock · Derivative 1,318,681 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · derivative · entry 5

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 439,560 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F6 · derivative.exercise_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F6 · derivative.expiration_date: The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 PurchaseCommon Stock 133,333 $15.00 $1,999,995.00
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 4

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners IV SBIC, LP

Disclosed balance after: 3,861,797

F5 · price: Reflects shares Hatteras Venture Partners IV SBIC, LP purchased in the initial public offering at the initial public offering price of $15.00 per share.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionCommon Stock 99,513 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 3

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By L2 Ventures, LLC

Disclosed balance after: 99,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F4 · ownership.nature: The reportable securities are owned directly by L2 Ventures, LLC ("L2 Ventures"). Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of L2 Ventures. The securities directly held by L2 Ventures are indirectly held by the individual managing members of HVA V (each, a "L2 Managing Member" and collectively, the "L2 Managing Members"). The L2 Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The L2 Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each L2 Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any L2 Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionCommon Stock 212,419 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 2

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras NC Fund, LP

Disclosed balance after: 212,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F3 · ownership.nature: The reportable securities are owned directly by Hatteras NC Fund, LP ("Hatteras NC"). Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC Fund, LP. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member" and collectively, the "HVA IV Managing Members"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
May 22, 2017 Filed May 24, 2017 20:18 UTC G1 Therapeutics, Inc. GTHX · Entity 87413 ConversionCommon Stock 3,728,464 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-17-035173 · doc4.xml · nonDerivative · entry 1

Thorp Clay · CIK 0001592380 · 10% owner

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner

Crumpler John · CIK 0001674107 · 10% owner

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner

LEE KENNETH B JR · CIK 0001208570 · 10% owner

Reed Douglas MD · CIK 0001291262 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Hatteras Venture Partners IV SBIC, LP

Disclosed balance after: 3,728,464

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted to Common Stock on a 1-for-3 basis.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
April 26, 2017 Filed Apr 27, 2017 20:27 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 1,132 $22.07 $24,983.24
Disclosure

SEC source: 0000895419-17-000037 · wf-form4_149332485988014.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,816

F1 · kind: Represents shares of Common Stock credited to the Reporting Person's 2017 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Read SEC document
March 31, 2017 Filed Apr 4, 2017 21:53 UTC Bausch Health Companies Inc. VRX · Entity 4363 GrantCommon Stock, no par value 2,120 $11.03 $23,383.60
Disclosure

SEC source: 0000885590-17-000021 · primary_doc.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,046

F1 · shares: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Read SEC document
March 02, 2017 Filed Mar 2, 2017 20:07 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 1,602 $6.24 $9,996.48
Disclosure

SEC source: 0001127602-17-009570 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,823

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

Read SEC document
January 25, 2017 Filed Jan 26, 2017 21:28 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 867 $28.83 $24,995.61
Disclosure

SEC source: 0000895419-17-000012 · wf-form4_148546606878580.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,684

F1 · kind: Represents shares of Common Stock credited to the Reporting Person's 2017 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Read SEC document
January 19, 2017 Filed Jan 19, 2017 19:31 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 7,592 $8.22 $62,406.24
Disclosure

SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 3

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,060,514

F4 · price: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
January 19, 2017 Filed Jan 19, 2017 17:53 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 6,478 $8.22 $53,249.16
Disclosure

SEC source: 0001578563-17-000002 · primary_doc.xml · nonDerivative · entry 3

Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner · May be part of a 13(d) Group

Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,757,719

F4 · price: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F5 · ownership.nature: HVP holds 1,611,407 shares and HVA holds 146,312 shares of the Issuer's common stock directly.

Read SEC document
January 18, 2017 Filed Jan 19, 2017 19:31 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 12,258 $8.64 $105,909.12
Disclosure

SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 2

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,068,106

F3 · price: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
January 18, 2017 Filed Jan 19, 2017 17:53 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 10,457 $8.64 $90,348.48
Disclosure

SEC source: 0001578563-17-000002 · primary_doc.xml · nonDerivative · entry 2

Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner · May be part of a 13(d) Group

Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,764,197

F3 · price: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
January 17, 2017 Filed Jan 19, 2017 19:31 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 9,806 $8.92 $87,469.52
Disclosure

SEC source: 0001578563-17-000004 · primary_doc.xml · nonDerivative · entry 1

Hatteras Venture Advisors IV SBIC, LLC · CIK 0001675236 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Partners IV SBIC, LP · CIK 0001675232 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,080,364

F1 · price: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
January 17, 2017 Filed Jan 19, 2017 17:53 UTC Clearside Biomedical, Inc. CLSD · Entity 82875 SaleCommon Stock 8,366 $8.92 $74,624.72
Disclosure

SEC source: 0001578563-17-000002 · primary_doc.xml · nonDerivative · entry 1

Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner · May be part of a 13(d) Group

Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner · May be part of a 13(d) Group

Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner · May be part of a 13(d) Group

Crumpler John · CIK 0001674107 · 10% owner · May be part of a 13(d) Group

INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner · May be part of a 13(d) Group

LEE KENNETH B JR · CIK 0001208570 · 10% owner · May be part of a 13(d) Group

Reed Douglas MD · CIK 0001291262 · 10% owner · May be part of a 13(d) Group

Thorp Clay · CIK 0001592380 · 10% owner · May be part of a 13(d) Group

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,774,654

F1 · price: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · ownership.nature: The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Read SEC document
December 30, 2016 Filed Jan 5, 2017 00:45 UTC Bausch Health Companies Inc. VRX · Entity 4363 GrantCommon Stock, no par value 1,463 $14.52 $21,242.76
Disclosure

SEC source: 0001219890-17-000001 · primary_doc.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,926

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Read SEC document
December 01, 2016 Filed Dec 2, 2016 19:09 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 1,788 $5.59 $9,994.92
Disclosure

SEC source: 0001127602-16-068910 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,221

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

Read SEC document
October 19, 2016 Filed Oct 20, 2016 20:33 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 1,115 $22.41 $24,987.15
Disclosure

SEC source: 0000895419-16-000204 · wf-form4_147699558184330.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,817

F1 · kind: Represents shares of Common Stock credited to the Reporting Person's 2016 deferral account under the Cree, Inc. Stock Compensation and Deferral Program, issuable following the Reporting Person's Separation of Service from Cree.

Read SEC document
September 30, 2016 Filed Oct 5, 2016 20:07 UTC Bausch Health Companies Inc. VRX · Entity 4363 GrantCommon Stock, no par value 865 $24.55 $21,235.75
Disclosure

SEC source: 0001677300-16-000010 · primary_doc.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,463

F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc.

Read SEC document
September 26, 2016 Filed Sep 28, 2016 18:32 UTC Novan, Inc. NOVN · Entity 111882 ConversionSeries 4 Preferred Stock · Derivative 27,777 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-030266 · doc4.xml · derivative · entry 2

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,777 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The preferred stock automatically converted into common stock on a 1-to-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: The preferred stock automatically converted into common stock on a 1-to-1 basis upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: The preferred stock automatically converted into common stock on a 1-to-1 basis upon the closing of the Issuer's initial public offering.

Read SEC document
September 26, 2016 Filed Sep 28, 2016 18:32 UTC Novan, Inc. NOVN · Entity 111882 ConversionCommon Stock 27,777 $0.00 $0.00
Disclosure

SEC source: 0000899243-16-030266 · doc4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 20, 2016 Filed Sep 22, 2016 16:44 UTC Novan, Inc. NOVN · Entity 111882 GrantStock Option · Derivative 14,484 $0.00 Strike: $11.00 $0.00
Disclosure

SEC source: 0000899243-16-029752 · doc4.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,484

Underlying: Common Stock · 14,484 shares

Expires 2026-09-19

F1 · derivative.exercise_date: The option vests in four equal quarterly installments, with the first installment vesting on December 20, 2016.

Read SEC document
September 01, 2016 Filed Sep 6, 2016 19:27 UTC BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 GrantCommon Stock 2,433 $4.11 $9,999.63
Disclosure

SEC source: 0001127602-16-061906 · form4.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,433

F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000.

Read SEC document
September 01, 2016 Filed Sep 6, 2016 21:11 UTC WOLFSPEED, INC. CREE · Entity 619 GrantCOMMON STOCK 6,429 $0.00 $0.00
Disclosure

SEC source: 0000895419-16-000188 · wf-form4_147319624949149.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,702

F1 · kind: Award of restricted stock units vesting in full on September 1, 2017.

Read SEC document
March 31, 2011 Filed Apr 4, 2011 20:06 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 709.421 $26.43 $18,750.00
Disclosure

SEC source: 0000060667-11-000083 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,429.879

Underlying: Common Stock · 709.421 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
December 31, 2010 Filed Jan 4, 2011 15:40 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 747.608 $25.08 $18,750.01
Disclosure

SEC source: 0000060667-11-000004 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,581.502

Underlying: Common Stock · 747.608 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
September 30, 2010 Filed Oct 4, 2010 15:10 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 841.184 $22.29 $18,749.99
Disclosure

SEC source: 0000060667-10-000171 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,679.939

Underlying: Common Stock · 841.184 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
June 30, 2010 Filed Jul 1, 2010 21:36 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 918.217 $20.42 $18,749.99
Disclosure

SEC source: 0000060667-10-000136 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,681.334

Underlying: Common Stock · 918.217 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
May 28, 2010 Filed Jun 2, 2010 15:56 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantDeferred Stock Units · Derivative 4,700 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000060667-10-000112 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,797.006

Underlying: Common Stock · 4,700 shares

Expires not disclosed

F1 · derivative.exercise_date: All Deferred Stock Units are immediately one hundred percent (100%) vested. The Company will issue one share of common stock in exchange for each Deferred Stock Unit upon termination of the holder's service as a member of the Board of Directors of the Company.

F1 · derivative.expiration_date: All Deferred Stock Units are immediately one hundred percent (100%) vested. The Company will issue one share of common stock in exchange for each Deferred Stock Unit upon termination of the holder's service as a member of the Board of Directors of the Company.

Read SEC document
May 27, 2010 Filed May 27, 2010 20:32 UTC LOWES COMPANIES INC LOW · Entity 2896 Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 8,000 $0.00 Strike: $21.13 $0.00
Disclosure

SEC source: 0000060667-10-000098 · edgardoc.xml · derivative · entry 3

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2010-05-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 27, 2010 Filed May 27, 2010 20:32 UTC LOWES COMPANIES INC LOW · Entity 2896 SaleCommon Stock 8,000 $24.68 $197,404.00
Disclosure

SEC source: 0000060667-10-000098 · edgardoc.xml · nonDerivative · entry 2

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: This transaction was executed in multiple trades at prices ranging from $24.67 to $24.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 27, 2010 Filed May 27, 2010 20:32 UTC LOWES COMPANIES INC LOW · Entity 2896 Exercise / conversionCommon Stock 8,000 $21.13 $169,040.00
Disclosure

SEC source: 0000060667-10-000098 · edgardoc.xml · nonDerivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2010 Filed Apr 1, 2010 19:11 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 773.515 $24.24 $18,750.00
Disclosure

SEC source: 0000060667-10-000072 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,667.454

Underlying: Common Stock · 773.515 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
December 31, 2009 Filed Jan 5, 2010 15:51 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 801.625 $23.39 $18,750.01
Disclosure

SEC source: 0000060667-10-000006 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,783.201

Underlying: Common Stock · 801.625 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
September 30, 2009 Filed Oct 2, 2009 15:53 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 895.415 $20.94 $18,749.99
Disclosure

SEC source: 0000060667-09-000130 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,860.585

Underlying: Common Stock · 895.415 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
June 30, 2009 Filed Jul 2, 2009 15:25 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 965.997 $19.41 $18,750.00
Disclosure

SEC source: 0000060667-09-000084 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,860.096

Underlying: Common Stock · 965.997 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
May 29, 2009 Filed Jun 2, 2009 14:18 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantDeferred Stock Units · Derivative 6,100 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000060667-09-000060 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,748.178

Underlying: Common Stock · 6,100 shares

Expires not disclosed

F1 · derivative.exercise_date: All Deferred Stock Units are immediately one hundred percent (100%) vested. The Company will issue one share of common stock in exchange for each Deferred Stock Unit upon termination of the holder's service as a member of the Board of Directors of the Company.

F1 · derivative.expiration_date: All Deferred Stock Units are immediately one hundred percent (100%) vested. The Company will issue one share of common stock in exchange for each Deferred Stock Unit upon termination of the holder's service as a member of the Board of Directors of the Company.

Read SEC document
March 31, 2009 Filed Apr 2, 2009 14:11 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 1,027.397 $18.25 $18,750.00
Disclosure

SEC source: 0000060667-09-000042 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,796.068

Underlying: Common Stock · 1,027.397 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
December 31, 2008 Filed Jan 2, 2009 22:38 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 871.283 $21.52 $18,750.01
Disclosure

SEC source: 0000060667-09-000006 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,664.828

Underlying: Common Stock · 871.283 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document
September 30, 2008 Filed Oct 2, 2008 15:12 UTC LOWES COMPANIES INC LOW · Entity 2896 GrantPhantom Stock · Derivative 791.473 $23.69 $18,750.00
Disclosure

SEC source: 0000060667-08-000150 · edgardoc.xml · derivative · entry 1

INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,697.467

Underlying: Common Stock · 791.473 shares

Expires not disclosed

F1 · security: Represents the credit of deferred compensation to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

F2 · derivative.exercise_price: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.exercise_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F2 · derivative.expiration_date: The Reporting Person becomes entitled to the cash value of the phantom stock upon ceasing to be a director of Lowe's.

F3 · balance_after: Includes the credit of dividends to the Reporting Person's deferred stock account under the Lowe's Deferred Compensation Program.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.